scholarly journals Breast Cancer in the Elderly: An Observational Study Investigating Compliance of Screening Mammography in an Underserved Community

2021 ◽  
Vol 12 (5) ◽  
pp. 155-164
Author(s):  
Shruti Sharma ◽  
Dixita Patel ◽  
Sushma Pavuluri ◽  
Amy Stein ◽  
Binal Patel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
The Elderly ◽  
Screening Mammography ◽  
Underserved Community

scholarly journals Multilevel Factors Impacting Mammography Screening Decisions in the Elderly: A Clinician and Patient Pilot

2020 ◽  
Author(s):  
Anthony Marcelo Chicaiza ◽  
Katherine Lopez ◽  
Kenneth W. Lin ◽  
Ranit Mishori ◽  
Dongyu Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Risk ◽  
Perceived Risk ◽  
Task Force ◽  
The Elderly ◽  
Screening Mammography ◽  
Research Network ◽  
Cancer Worry ◽  
Patient Decision Making ◽  
New Research

Abstract Background For women age 75 and older, there is insufficient evidence to recommend routine breast cancer screening, as the benefits may not outweigh harms. The objective of this study was to identify variables that clinicians consider influential when making screening mammography recommendations for these women and to assess the acceptability and feasibility of a patient print intervention designed to support patient decision-making and patient-clinician communication about stopping mammography. Methods Primary care clinicians who were part of a practice-based research network and patients aged 74–85 from this network completed surveys online and by phone, respectively. Results Twenty-two clinicians (18% response rate) completed the survey. The mean age at which clinicians reported that they would stop recommending screening mammography was 77.14 years. Clinicians were most likely to cite patient comorbidity [86.4%], functional status [77.3%], and cancer family history [63.6%], as well as U.S. Preventive Services Task Force (USPSTF) guidelines [81.8%] and new research regarding screening mammography [77.3%] as factors influencing their recommendations. Fourteen patients (70% enrollment rate) completed baseline surveys and received personalized booklets. Eleven (79% retention) completed follow-up surveys, reporting high intervention acceptability. Decreases in perceived breast cancer risk were significant for lifetime perceived risk (M = 26.91 vs. 4.18, p = < 0.01). Cancer worry decreased slightly (M = 1.27 vs. 1.09, p = 0.77). Conclusions An intervention that addresses a patients’ cancer risk and comorbidities that aligns with USPSTF guidelines appears feasible and acceptable to patients and aligns with clinicians’ values.

A Multicentric non-interventional observational study to determine treatment patterns and response of drugs in various stages of breast cancer along with epidemiology

2020 ◽  
Vol 8 (2) ◽  
pp. 71-81
Author(s):  
Mukkamala Durga Niharika ◽  
Shaik Kulsumbi ◽  
Devagiri Anupama ◽  
Tadigiri Vineela Supriya ◽  
Kotari Navya ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
Receptor Expression ◽  
Breast Cancer Patients ◽  
Female Patients ◽  
Life Threatening ◽  
Guntur District ◽  
Study Population ◽  
Hormone Receptor Expression

Cancer is a life-threatening disease which causes to lose cohesiveness and orderliness of normal tissue. These malignant cells can spread to any other organ through blood flow or lymphatic flow and develop malignancy over there; this phenomenon is called metastasis. The aim is to focus on treatment pattern and response of drugs in various stages of breast cancer along with epidemiology. It is a non- interventional multicentric observational study. Female patients confirmed with Breast cancer are included in the study. All the relevant data were collected on a patient demographic form after obtaining informed consent from individual patients. In our study, the mean age of presentation in breast cancer patients was 41.35 years. Further it was found that 40.5% (n = 81) majority-female patients with Breast cancer are from Guntur District and 21.5% (n= 43). The majority of women with Breast cancer have hormone receptor expression of ER+/PR+HER2- was found to be 33% (n= 50). In the study on analyzing comorbidities of the study population, it was noted that 28.5% of women were affected with Diabetes mellitus. In our study, it was found that most of the patients with Breast cancer have been most often prescribed with Adriamycin 27.86%. From these observations, we conclude that late menarche may be one of the etiological causes of breast cancer in women, Invasive carcinoma in situ is the most commonly reported breast cancer in the study. Patients have been diagnosed with breast cancer at their stage 3 of progression, which may be the reason for making it mandatory for more than 50% of patients to undergo 6 to 8 cycles of chemotherapy. Coming to the patterns of drug use, ADRIAMYCIN, CYCLOPHOSPHAMIDE and DOCETAXEL are the three most commonly used single drug and combinational drug therapies among the study population.

Management of early stage breast cancer in the elderly

Aging Health ◽  
2006 ◽  
Vol 2 (2) ◽  
pp. 245-251
Author(s):  
Joanne E Mortimer ◽  
Sarah L Blair
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
The Elderly ◽  
Early Stage Breast Cancer

scholarly journals Safety of High-Dose Dabigatran in Elderly and Younger Patients with a Low Bleeding Risk: A Prospective Observational Study

Cardiology ◽  
2021 ◽  
pp. 1-5
Author(s):  
Aharon Erez ◽  
Gregory Golovchiner ◽  
Robert Klempfner ◽  
Ehud Kadmon ◽  
Gustavo Ruben Goldenberg ◽  
...  
Keyword(s):  
Observational Study ◽  
Elderly Patients ◽  
Prospective Observational Study ◽  
Bleeding Risk ◽  
The Elderly ◽  
High Dose ◽  
World Population ◽  
Younger Patients ◽  
End Point

<b><i>Introduction:</i></b> In patients with atrial fibrillation (AF) at risk for stroke, dabigatran 150 mg twice a day (DE150) is superior to warfarin for stroke prevention. However, there is paucity of data with respect to bleeding risk at this dose in elderly patients (≥75 years). We aimed to evaluate the safety of DE150 in comparison to warfarin in a real-world population with AF and low bleeding risk (HAS-BLED score ≤2). <b><i>Methods:</i></b> In this prospective observational study, 754 consecutive patients with AF and HAS-BLED score ≤2 were included. We compared outcome of elderly patients (age ≥75 tears) to younger patients (age &#x3c;75 years). The primary end point was the combined incidence of all-cause mortality, stroke, systemic emboli, and major bleeding event during a mean follow-up of 1 year. <b><i>Results:</i></b> There were 230 (30%) elderly patients, 151 patients were treated with warfarin, and 79 were treated with DE150. Fifty-two patients experienced the primary endpoint during the 1-year follow-up. Among the elderly, at 1-year of follow-up, the cumulative event rate of the combined endpoint in the DE150 and warfarin was 8.9 and 15.9% respectively (<i>p</i> = 0.14). After adjustment for age and gender, patients who were treated with DE150 had a nonsignificant difference in the risk for the combined end point as patients treated with warfarin both among the elderly and among the younger population (HR 0.58, 95% C.I = 0.25–1.39 and HR = 1.12, 95% C.I 0.62–2.00, respectively [<i>p</i> for age-group-by-treatment interaction = 0.83). <b><i>Conclusions:</i></b> Our results suggest that Dabigatran 150 mg twice a day can be safely used among elderly AF patients with low bleeding risk.

Sign in / Sign up

Export Citation Format

Share Document